AMY VAN MILLIGAN: Open Payments
NPI 1841221538 · RIPLEY, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$617 in 28 payments from 10 companies in 2025. Trend: 2023 $275 · 2024 $415 · 2025 $617
Food & beverage: $617
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $177 |
| Indivior Inc. | 4 | $143 |
| ABBVIE INC. | 2 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $52 |
| Braeburn Inc. | 3 | $47 |
| Luye Pharma (USA) Ltd. | 3 | $42 |
| Axsome Therapeutics, Inc. | 1 | $39 |
| Alkermes, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: CAPLYTA, SUBLOCADE, MAVYRET, INGREZZA, BRIXADI, ERZOFRI EXTENDED-RELEASE, Auvelity, VIVITROL.
Industry payments across OH — which companies pay providers there.
